Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151775 · ClinicalTrials.gov registry record · Phase 2
Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 362
- Enrollment target
NCT00151775 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 362 participants.
The verdict
NCT00151775, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 362 participants
- Enrollment target
Study Summary
This study assesses the efficacy and safety of olmesartan medoxomil in children ages 1-16 with high blood pressure. After a 5-week blinded treatment period of up to 5 weeks participants can continue to take olmesartan medoxomil (OM) for up to an additional 46 weeks.
Interventions
- DRUG placebo
- DRUG olmesartan medoxomil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00151775
The ClinicalTrials.gov registry entry for NCT00151775 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 362 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00151775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00151775 about?
NCT00151775 is a clinical study titled "Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure". This study assesses the efficacy and safety of olmesartan medoxomil in children ages 1-16 with high blood pressure. After a 5-week blinded treatment period of up to 5 weeks participants can continue to take olmesartan medoxomil (OM) for up to an additional 46 weeks.
What is the current status of trial NCT00151775?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 362 participants. The study started on 2005-05. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00151775?
The interventions under investigation include: placebo (DRUG), olmesartan medoxomil (DRUG).
Who is sponsoring clinical trial NCT00151775?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.